Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 6, 2002, Pages 565-575

  Kumar, Ritesh N ^a   Raisch, Dennis ^b   Borrego, Matthew E ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cost effectiveness; Lipid lowering therapies; Pharmacoeconomics; Research quality; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ACCURACY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE POLICY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RELIABILITY; REVIEW; RISK FACTOR; SCORING SYSTEM; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 0036899727     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.6.565     Document Type: Review

References (64)

1. Hahn RA, Heath GW, Chang MH. Cardiovascular disease risk factors and preventive practices among adults - United States, 1994: a behavioral risk factor atlas. Behavioral risk factor surveillance system state co-ordinators. Morbidity ? Mortality Weekly Report. CDC Surveillance Summaries 47 (5), 35-69 (1998).
2. LaRosa JC, Hunninghake D, Bush D et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation 872, 1721-1733 (1990).
3. Pekkaneh J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 324(1), 60-61 (1991).
4. Scott R. Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 24(5), A26-A28 (1997).
5. Plans-Rubio P. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Pub. Health 111, 33-40 (1997).
6. Gonzalez ER. Preventing cardiovascular athlerosclerosis: Role of HMG-CoA inhibitors. Formulary 31, 582-602 (1996).
7. Bradley CA, Iskedjian M, Lancot KL et al. Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Ann. Pharmacother. 29, 681-689 (1995).
8. Iskedjian M, Trakas K, Bradley CA et al. Quality assessment of economic evaluations published in pharmacoeconomics. PharmacoEconomics 12, 685-694 (1997).
9. Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann. Pharmacother. 27, 1126-1133 (1993).
10. ISPOR Lexicon. 1: 18. Pashos CL, Mein EG, Wanke LA (Eds).
11. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA 258(17), 2381-2387(1987).
12. Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA 259(15), 2249-2254 (1988).
13. Martens LL, Rutten FF, Erkelens DW et al. Cost-effectiveness of cholesterol-lowering therapy in the Netherlands. Simvastatin venus cholestyramine. Am. J. Med 87(4A), 54S-58S(1989).
14. Martens LL, Rutten FF, Erkelson DW, Ascoop CA. Clinical benefits and cost-effectiveness of lowering senun cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am. J. Cardiol. 65, 27f-32f (1990).
15. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAAM 265(9), 1145-1151 (1991).
16. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am. J. Cardiol. 67(9), 789-796 (1991).
17. Kristiansen IS, Eggen AE, Thelle DS. Cost-effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worthwhile? Br. Med. J. 302, 1119-1122 (1991).
18. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine. PharmacoEconomics 1(3), 213-216 (1992).
19. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J. Cardiol. 72, 75D-79D (1993).
20. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin. Ther. 16(6), 1052-1062 (1994).
21. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 273(13), 1032-1038 (1995).
22. Ashraf T, Hay JW, Pitt B et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am. J. Cardiol 78, 409-414 (1996).
23. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian simvastatin survival study (4S). Eur. Heart J. 17, 1001-1007 (1996).
24. Johannesson M, Borgquist L, Jonsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary healthcare. J. Int. Med 240, 23-29 (1996).
25. Perrault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc. Drugs Ther. 10, 787-794 (1996).
26. Pharoah PD, Hollingworth W. Cost-effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Br. Med. J. 312, 1443-1448 (1996).
27. Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br. Med. J. 315, 1577-1582(1997).
28. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N. Engl. J. Med. 336(5), 332-336 (1997).
29. Riviere M, Wang S, Leclerc C, Fitzsimon C, Treriak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can. Med. Assoc. J. 156(7), 991-997 (1997).
30. Huse DM, Russel MW, Miller JD et al. Cost-effectiveness of statins. Am. J. Cardiol. 82, 1357-1363(1998).
31. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 137(Suppl.), S111-S116 (1998).
32. Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher doses of lovastatin cost-effective? Arch. Intern. Med 158, 375-381 (1998).
33. Plans-Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. J. Tech. Assess. Healthcare 14 (2), 320-330 (1998).
34. Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Suppl. C), C59-C65 (1998).
35. Elliott W, Weir D. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am. J. Health-Syst. Pharm. 56, 1726-1732 (1999).
36. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryi-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch. Intern. Med. 159, 593-600 (1999).
37. Pickin DM, McCabe CJ, Ramsay LE et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82 (3), 325-332 (1999).
38. Ganz DA, Kuntz KM, Jacobson CA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methyglutary coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann. Intern. Med. 132(10), 780-787 (2000).
39. Prosser LA, Stinnet AA, Goldman PA et al. Cost-effectiveness of cholesterol lowering therapies according to selected patient characteristics. Ann. Intern. Med. 132(10), 769-779 (2000).
40. Sarma S, Fifer SK Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. Drugs 40(Suppl. 1), 42-52 (1990).
41. Schulman KA, Kinosian B, Jacobson TA et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 264(23), 3025-3033 (1990).
42. Lim MC, Foo WM. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia. Ann. Acad. Med. 21(1), 34-37 (1992).
43. Kinlay S, O'Connell D, Evans D, Halliday J. The cost-effectiveness of different blood-cholesterol-lowering strategies in the prevention of coronary heart disease. Aust. J. Pub. Health 18(1), 105-110 (1994).
44. Smart AJ, Walters L. Pharmacoeconomic assessment of the HMG-CoA reductase inhibitors. S. Afr. Med. J. 84, 834-837 (1994).
45. McGehee MM, Johnson EQ, Rasmussen HM, Sahyoun N, Lynch MM, Carey M. Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. J. Am. Diet Assoc. 95(9), 1041-1043 (1995).
46. Schrott HG, Stein EA, Dujovne CA et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am. J. Cardiol. 75, 34-39 (1995).
47. Tomson Y, Johannesson M, Aberg H. The costs and effects of two different lipid intervention programmes in primary healthcare. J. Intern. Med. 237(1), 13-17 (1995).
48. Oster G, Borok GM, Menzin J et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch. Int. Med. 156, 731-739 (1996).
49. Brannon SD, Tershakovec AM, Shannon BM. The cost-effectiveness of alternative methods of nutritional education for hypercholesterolemic children. Am. J. Public Health 87(12), 1967-1970 (1997).
50. Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am. J. Cardiol. 80, 799-802 (1997).
51. Kirchgassler KU, Schiffner-Rohe J, Stahlheber U. Cost effectiveness of miconised fenofibrate and simvastatin in the short-term treatment of Type IIa and Type IIb hyperlipidaemia. PharmacoEconomics 12(2 Pt 2), 237-246 (1997).
52. Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-effectiveness of initial therapy with 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed care organization. Clin. Ther. 19(3), 582-602 (1997).
53. Koren MJ, Smith DG, Hunninghake DB et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. PharmacoEconomics 14(1), 59-70 (1998).
54. Naglak M, Mitchell DC, Kris-Etherton P, Harkness W, Pearson TA. What to consider when conducting a cost-effectiveness analysis in a clinical setting. J. Am. Diet Assoc. 98(10), 1149-1154 (1998).
55. Pederson TR. Coronary artery disease: the Scandinavian simvastatin survival study experience. Am. J. Cardiol. 82(10B), 53T-56T (1998).
56. Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the surrogate marker cost-efficacy (SmaC) study. Clin. Ther. 21(10), 1788-1796 (1999).
57. Cobos A, Jovell AJ, Garcia-Altes A, Garcia-Closas R, Serra-Majem L. Which statin is most efficient for the treatment of hypercholesrerolemia? A cost-effectiveness analysis. Clin. Ther. 21 (11), 1924-1936 (1999).
58. Hilleman DE, Woodruff MP, Holmberg MJ, Wurdeman RL, Ryschon KI., Seyedroudbari A. Comparative cost-effectiveness of fluvastatin and lovastatin in patients with hypercholesterolemia. J. Managed Care Pharm. 6(3), 241-246 (2000).
59. Sikand G, Kashyap ML, Wong ND, Hsu JC. Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance. J. Am. Diet Assoc. 100 (2), 218-224 (2000).
60. Oster G, Borok GM, Menzin J et al. A randomized trial to assess the effectiveness and cost in clinical practice: Rationale and design of the cholesterol reduction intervention study (CRIS). Control Clin. Trials 16, 3-16 (1995).
61. Tolman KG. The liver and lovastatin. Am. J. Cardiol. 15;89(12), 1374-1380 (2002).
62. Gold MR, Siegel JE, Russell LB, Weinstein MC. Panel on Cost Effectiveness in Health and Medicine. Appendix A: Summary Recommendations. In: Cost Effectiveness in Health and Medicine. Oxford University Press, New York, USA, 304-311 (1996).
63. Morris S. A comparison of economic modeling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 6(6), 589-601 (1997).
64. Drummond MF, Davies L. Economic analysis alongside clinical trials. Int. J. Technol. Assessment in Healthcare 7, 561-573 (1991).